PEGylated Proteins Market by Product, Protein Type, Indication, End-User

List of Tables

The PEGylated Proteins Market is projected to reach USD 2.81 billion by 2030 from USD 1.30 billion in 2022, at a CAGR of 10.04% during the forecast period.

Global PEGylated Proteins Market

KEY MARKET STATISTICS
Base Year Value [2022]	USD 1.30 billion
Estimated Year Value [2023]	USD 1.43 billion
Forecast Year Value [2030]	USD 2.81 billion
CAGR (%)	10.04%

Market Segmentation & Coverage:

This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the PEGylated Proteins Market.

Based on Product, market is studied across PEGylation Kits, PEGylation Reagents, and Services. The PEGylation Reagents is further studied across Biofunctional PEGs, Branched PEGs, Monofunctional Linear PEGs, and Multi-Arm PEGs. The PEGylation Reagents is projected to witness significant market share during forecast period.

Based on Protein Type, market is studied across Colony-Stimulating Factor, Erythropoietin, Interferons, mAbs, and Recombinant Factor VII. The Colony-Stimulating Factor is projected to witness significant market share during forecast period.

Based on Indication, market is studied across Autoimmune Diseases, Cancer, Gastrointestinal Disorders, Hemophilia, Hepatitis, and Multiple Sclerosis. The Autoimmune Diseases is projected to witness significant market share during forecast period.

Based on End-User, market is studied across Academic & Research Institutes, CROs, and Pharmaceutical & Biopharmaceutical Companies. The CROs is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa is projected to witness significant market share during forecast period.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is an indispensable tool for assessing the PEGylated Proteins Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.

Market Share Analysis:

The Market Share Analysis offers invaluable insights into the vendor landscape PEGylated Proteins Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.

Key Company Profiles:

The report delves into recent significant developments in the PEGylated Proteins Market, highlighting leading vendors and their innovative profiles. These include Abcam PLC, Aurigene Pharmaceutical Services Limited, Biogen Inc., BioMarin, Biomatrik Inc., Celares GmbH, Creative PEGWorks, Enzon Pharmaceuticals, Inc., Exelead, F. Hoffmann-La Roche Ltd., Horizon Therapeutics PLC, Iris Biotech GmbH, JenKem Technology USA Inc., Laysan Bio, Inc., Ligand Pharmaceuticals Inc, Merck KGaA, NOF CORPORATION, Novo Nordisk A/S, Pfizer Inc., Profacgen, Quanta BioDesign Ltd, QuiaPEG Pharmaceuticals Holding AB, Takeda Pharmaceuticals Company Limited, Thermo Fisher Scientific Inc., and UCB S.A..

The report offers valuable insights on the following aspects:

1. Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.

2. Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.

3. Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.

4. Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.

5. Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast for the PEGylated Proteins Market?

2. Which products, segments, applications, and areas hold the highest investment potential in the PEGylated Proteins Market?

3. What is the competitive strategic window for identifying opportunities in the PEGylated Proteins Market?

4. What are the latest technology trends and regulatory frameworks in the PEGylated Proteins Market?

5. What is the market share of the leading vendors in the PEGylated Proteins Market?

6. Which modes and strategic moves are suitable for entering the PEGylated Proteins Market?

Product Code: MRR-69324464D11D

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. PEGylated Proteins Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising prevalence of chronic diseases among population
  - 5.1.1.2. Growing investments in pharmaceutical research and development programs
  - 5.1.1.3. Modernization of healthcare infrastructure across economies
- 5.1.2. Restraints
  - 5.1.2.1. High costs associated with PEGylation process
- 5.1.3. Opportunities
  - 5.1.3.1. Higher emphasis on biotechnology and biomolecular engineering
  - 5.1.3.2. Potential of PEGylation in target specific drug delivery
- 5.1.4. Challenges
  - 5.1.4.1. Time consuming stringent drug approval processes
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. PEGylated Proteins Market, by Product

6.1. Introduction
6.2. PEGylation Kits
6.3. PEGylation Reagents
- 6.4.1. Biofunctional PEGs
- 6.4.2. Branched PEGs
- 6.4.3. Monofunctional Linear PEGs
- 6.4.4. Multi-Arm PEGs
6.4. Services

7. PEGylated Proteins Market, by Protein Type

7.1. Introduction
7.2. Colony-Stimulating Factor
7.3. Erythropoietin
7.4. Interferons
7.5. mAbs
7.6. Recombinant Factor VII

8. PEGylated Proteins Market, by Indication

8.1. Introduction
8.2. Autoimmune Diseases
8.3. Cancer
8.4. Gastrointestinal Disorders
8.5. Hemophilia
8.6. Hepatitis
8.7. Multiple Sclerosis

9. PEGylated Proteins Market, by End-User

9.1. Introduction
9.2. Academic & Research Institutes
9.3. CROs
9.4. Pharmaceutical & Biopharmaceutical Companies

10. Americas PEGylated Proteins Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific PEGylated Proteins Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa PEGylated Proteins Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player

14. Competitive Portfolio

14.1. Key Company Profiles
- 14.1.1. Abcam PLC
- 14.1.2. Aurigene Pharmaceutical Services Limited
- 14.1.3. Biogen Inc.
- 14.1.4. BioMarin
- 14.1.5. Biomatrik Inc.
- 14.1.6. Celares GmbH
- 14.1.7. Creative PEGWorks
- 14.1.8. Enzon Pharmaceuticals, Inc.
- 14.1.9. Exelead
- 14.1.10. F. Hoffmann-La Roche Ltd.
- 14.1.11. Horizon Therapeutics PLC
- 14.1.12. Iris Biotech GmbH
- 14.1.13. JenKem Technology USA Inc.
- 14.1.14. Laysan Bio, Inc.
- 14.1.15. Ligand Pharmaceuticals Inc
- 14.1.16. Merck KGaA
- 14.1.17. NOF CORPORATION
- 14.1.18. Novo Nordisk A/S
- 14.1.19. Pfizer Inc.
- 14.1.20. Profacgen
- 14.1.21. Quanta BioDesign Ltd
- 14.1.22. QuiaPEG Pharmaceuticals Holding AB
- 14.1.23. Takeda Pharmaceuticals Company Limited
- 14.1.24. Thermo Fisher Scientific Inc.
- 14.1.25. UCB S.A.
14.2. Key Product Portfolio

15. Appendix

15.1. Discussion Guide
15.2. License & Pricing